JP2021192797A - Providing method of double-sided printing information of combination tablet utilizing pharmaceutical packaging box - Google Patents

Providing method of double-sided printing information of combination tablet utilizing pharmaceutical packaging box Download PDF

Info

Publication number
JP2021192797A
JP2021192797A JP2021133370A JP2021133370A JP2021192797A JP 2021192797 A JP2021192797 A JP 2021192797A JP 2021133370 A JP2021133370 A JP 2021133370A JP 2021133370 A JP2021133370 A JP 2021133370A JP 2021192797 A JP2021192797 A JP 2021192797A
Authority
JP
Japan
Prior art keywords
tablet
packaging box
printed
combination
pharmaceutical packaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021133370A
Other languages
Japanese (ja)
Other versions
JP7334218B2 (en
Inventor
大輔 辻久
Daisuke Tsujihisa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohara Pharmaceutical Co Ltd
Original Assignee
Ohara Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohara Pharmaceutical Co Ltd filed Critical Ohara Pharmaceutical Co Ltd
Publication of JP2021192797A publication Critical patent/JP2021192797A/en
Application granted granted Critical
Publication of JP7334218B2 publication Critical patent/JP7334218B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Cartons (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

To create a method excellent in visual confirmation of drug information printed on double sides of a combination tablet in the packed state.SOLUTION: There is provided a pharmaceutical packaging box in which images on the surface and on the rear face of a combination tablet stored inside a box are described on a part. Preferably, on the surface of the combination tablet stored inside the box, a character string indicating ingredients or its abbreviated title, excluding a character string showing a dosage form, a content and a company name from a character string of a sales name, is printed, and on the rear face of the combination tablet, respective general names or abbreviated titles of two or more medicinal ingredients contained in the combination tablet are printed.SELECTED DRAWING: Figure 3

Description

本発明は、医薬品情報の提供方法を改善した医薬品製品の包装箱に関するものである。本発明の医薬品製品の包装箱は、箱を開封して中身の錠剤製品を取り出す手間を要せずとも、錠剤の両面に印字された情報を視認することが可能である。 The present invention relates to a packaging box for a pharmaceutical product having an improved method for providing pharmaceutical information. The packaging box for the pharmaceutical product of the present invention can visually recognize the information printed on both sides of the tablet without the trouble of opening the box and taking out the tablet product inside.

医薬品製品の包装箱は、ＰＴＰシートに封入された錠剤や、散剤、注射剤、点眼液などが詰められて、薬局等の医療現場へと提供されている。医薬品製品の包装箱の表面には、医療従事者が使用する際の利便性の向上や医療過誤の防止等を目的として、薬剤の名称や製剤中の薬物含量、医療用途などの様々な医薬品情報が記載されることは現在一般的に行われている。 Packaging boxes for pharmaceutical products are packed with tablets enclosed in PTP sheets, powders, injections, eye drops, and the like, and are provided to medical sites such as pharmacies. On the surface of the packaging box for pharmaceutical products, various drug information such as the name of the drug, the content of the drug in the drug, and the medical use are used for the purpose of improving convenience when used by medical professionals and preventing medical malpractice. Is now commonly described.

現在、医薬品情報が記載される試みは包装箱に対して限られて行われておらず、錠剤自体に対しても行われている。錠剤自体に医薬品情報を記載する方法は、薬剤師等の医療従事者による医療過誤の防止や患者の誤飲の防止につながる利点が一般的に知られている。錠剤自体に記載される情報としては、薬効成分の一般名又はその略称、含有量、製造販売会社名等が挙げられる。錠剤に文字を印字する行為は、レーザー光やインクジェットによる鮮明な文字の錠剤への印字が近年になって可能になるとともに、より広く行われるようになった。しかし文字が印字された錠剤は、錠剤製品全体中における割合が充分に高いといえないのが現状であり、更なる普及に向けての取り組みが必要とされる。 At present, attempts to describe drug information are not limited to packaging boxes, but also to tablets themselves. It is generally known that the method of writing drug information on the tablet itself has an advantage of preventing medical malpractice by a medical worker such as a pharmacist and preventing accidental ingestion by a patient. Examples of the information described on the tablet itself include the common name of the medicinal ingredient or its abbreviation, the content, the name of the manufacturing and sales company, and the like. The act of printing letters on tablets has become more widespread in recent years as it has become possible to print clear letters on tablets by laser light or inkjet. However, it cannot be said that the proportion of tablets with characters printed on them is sufficiently high in all tablet products, and it is necessary to make efforts for further popularization.

錠剤の種類には単一の薬効成分を含む単剤であるものと２以上の薬効成分を含む配合剤であるもの（配合錠）があるが、配合錠に対しても医薬情報が印字される試みは行われている。配合錠は２以上の薬効成分を含むため、単一の薬効成分を含む単剤の錠剤と比べて、錠剤に記載すべき薬剤に関する情報は当然に多くなる。そのため配合錠においては、必要な多くの情報を盛り込むために錠剤の両面を用いる必要性が非常に高くなる。
だが一般的に、包装箱に収容されている錠剤には含有する薬効成分の光や湿度等に対する安定性を確保する工夫を施した包装がなされ、其の包装状態にある錠剤の視認性は非常に悪い。例えば、錠剤はＰＴＰシートに封入された状態にあるものが多く、その状態では錠剤の片面の視認が可能でも、両面を視認することは困難である。そのため現状では、錠剤の両面で異なる情報が印字されていることは、其の情報の薬剤師による視認や患者に手渡す際の説明の困難性から必ずしも望ましいとはいえない。よって、配合錠の両面に異なる情報を印字する試みはあまり積極的に好ましいと言えないのが現状である。
そこで本発明者は、配合錠の両面に異なる情報が印字されることの利便性を広く推進するため、包装状態にあっても配合錠の両面に印字された情報が簡便に視認によって確認できる方法の開発を目指した。 There are two types of tablets, one is a single agent containing a single medicinal ingredient and the other is a combination drug containing two or more medicinal ingredients (combination tablet), but the drug information is also printed on the combination tablet. Attempts are being made. Since a combination tablet contains two or more medicinal ingredients, there is naturally more information about the drug to be described on the tablet than a single tablet containing a single medicinal ingredient. Therefore, in combination tablets, it becomes very necessary to use both sides of the tablet in order to incorporate a large amount of necessary information.
However, in general, the tablets contained in the packaging box are packaged with a device to ensure the stability of the medicinal ingredients contained in them against light, humidity, etc., and the visibility of the tablets in the packaged state is very high. Bad for. For example, many tablets are enclosed in a PTP sheet, and in that state, even if one side of the tablet can be visually recognized, it is difficult to visually recognize both sides. Therefore, at present, it is not always desirable that different information is printed on both sides of the tablet because it is difficult for the pharmacist to visually recognize the information and explain it when handing it to the patient. Therefore, the current situation is that attempts to print different information on both sides of the combination tablet are not very positive.
Therefore, the present inventor widely promotes the convenience of printing different information on both sides of the combination tablet, so that the information printed on both sides of the combination tablet can be easily visually confirmed even in the packaged state. Aimed at the development of.

意匠登録３１９６２２５号公報Design Registration No. 3196225

本発明が解決しようとする課題は、包装状態にある配合錠の両面に印字された医薬品情報の視認による確認に優れた方法を創出することである。 An object to be solved by the present invention is to create an excellent method for visually confirming drug information printed on both sides of a combination lock in a packaged state.

本発明者は、前記課題を解決するために鋭意検討し、医薬品の包装箱の表面に配合錠の両面の画像を載せることで、医薬品包装箱を開封することも要せずに包装状態にある配合錠の両面に印字された各々の情報が簡便に確認可能であることを見出し、本発明を完成するに至った。 The present inventor has studied diligently in order to solve the above-mentioned problems, and by placing images of both sides of the combination tablet on the surface of the packaging box of the drug, the packaging box is in a packaged state without the need to open the packaging box. We have found that each information printed on both sides of the combination tablet can be easily confirmed, and have completed the present invention.

すなわち本発明は、或る錠剤の表面（上面と同義）と裏面（下面と同義）の各々に記載された異なる情報が表示された医薬品包装箱又は其れを用いた医薬品情報の提供方法に関するものであり、其の好ましい態様は下記（１）〜（５）に記述されたものである。
（１）箱内部に収容された配合錠の表面と裏面の画像が一部分に記載されている医薬品包装箱。
（２）箱内部に収容された配合錠の表面には、販売名として使用される文字列から剤形、含量、会社名を示す文字列を除いた、配合成分を示す文字列又はその略称が印字され、配合錠の裏面には、配合錠に含まれる２以上の薬効成分の各々の一般名又は略称が印字された、前記（１）に記載の医薬品包装箱。
（３）箱内部に収容された配合錠の表面には、配合錠との文字列が印字され、配合錠の裏面には、２以上の薬効成分の各々の含量をｍｇ又はμｇの単位で示す数字が印字された、前記（２）に記載の医薬品包装箱。
（４）配合錠の表面と裏面の画像が写真又は絵図である、前記（１）〜（３）のいずれかに記載の医薬品包装箱。
（５）配合錠が、バルサルタン及びアムロジピンベシル酸塩、アジルサルタン及びアムロジピンベシル酸塩、カンデサルタン及びアムロジピンベシル酸塩、カンデサルタン及びヒドロクロロチアジド、イルベサルタン及びアムロジピンベシル酸塩、オルメサルタンメドキソミル及びアゼルニジピン、バルサルタン及びヒドロクロロチアジド、クロピドグレル硫酸塩及びアスピリン、テルミサルタン及びアムロジピン、テルミサルタン及びヒドロク
ロロチアジド、トラマドール及びアセトアミノフェン、ロサルタンカリウム及びヒドロクロロチアジド、のいずれかの２つの薬効成分を含む、前記（１）〜（４）のいずれかに記載の医薬品包装箱。 That is, the present invention relates to a drug packaging box in which different information described on each of the front surface (synonymous with the upper surface) and the back surface (synonymous with the lower surface) of a certain tablet is displayed, or a method for providing drug information using the same. The preferred embodiment thereof is described in the following (1) to (5).
(1) A pharmaceutical packaging box in which images of the front and back surfaces of a combination lock housed inside the box are partially described.
(2) On the surface of the combination tablet housed inside the box, there is a character string indicating the compounding ingredient or its abbreviation, excluding the character string indicating the dosage form, content, and company name from the character string used as the brand name. The pharmaceutical packaging box according to (1) above, wherein the generic name or abbreviation of each of the two or more medicinal ingredients contained in the combination tablet is printed on the back surface of the combination tablet.
(3) The character string of the combination tablet is printed on the front surface of the combination tablet housed inside the box, and the content of each of the two or more medicinal ingredients is indicated in mg or μg on the back surface of the combination tablet. The pharmaceutical packaging box according to (2) above, on which numbers are printed.
(4) The pharmaceutical packaging box according to any one of (1) to (3) above, wherein the images of the front surface and the back surface of the combination tablet are photographs or pictures.
(5) Combination tablets include balsartan and amlodipine besylate, azilsartan and amlodipine besylate, candesartan and amlodipine besylate, candesartan and hydrochlorothiazide, ilbesartan and amlodipine besylate, ormesartan medoxomil and azernidipine, balsartan and hydrochlorothiazide. The pharmaceutical agent according to any one of (1) to (4) above, which comprises two medicinal components of sulfate and aspirin, thermisartan and amlodipine, thermisartan and hydrochlorothiazide, tramadol and acetaminophen, rosartan potassium and hydrochlorothiazide. Packaging box.

本発明によって医薬品の包装箱の表面に配合錠の両面の画像を載せることで、包装状態のままで配合錠の両面に印字された各々の情報が視認可能となり、薬剤師や患者等に錠剤の両面に印字された情報を容易に伝達可能となった。尚、本発明の包装箱には、錠剤製品が手元になくなった後も包装箱さえあれば錠剤の両面に印字された情報が確認可能であるため、箱自体が医療関係者や患者に対する説明用の道具として更に独立して利用可能となる効果を有する。 According to the present invention, by placing images of both sides of the combination tablet on the surface of the packaging box of a pharmaceutical product, each information printed on both sides of the combination tablet can be visually recognized in the packaged state, and both sides of the tablet can be visually recognized by pharmacists, patients, etc. It became possible to easily transmit the information printed on the. Since the information printed on both sides of the tablet can be confirmed in the packaging box of the present invention as long as the packaging box is available even after the tablet product is no longer available, the box itself is for explanation to medical personnel and patients. It has the effect of being able to be used independently as a tool for.

図１は、本発明を適用する医薬品製品の包装箱の展開図の表面の例である。図中の点線は、フラップが切り離しやすい加工がされた箇所を表している。FIG. 1 is an example of the surface of a developed view of a packaging box for a pharmaceutical product to which the present invention is applied. Dotted lines in the figure represent the parts where the flaps are easily separated. 図２は、本発明を適用する医薬品製品の包装箱が成形されて且つ閉じられた状態の斜視図の例である。FIG. 2 is an example of a perspective view of a packaging box of a pharmaceutical product to which the present invention is applied in a molded and closed state. 図３は、包装箱に記載された錠剤の両面の画像の表示方法の例である。FIG. 3 is an example of a method of displaying images on both sides of a tablet described on a packaging box. 図４は、配合錠の表面の例である。点線の円は、配合成分や販売会社等を示す任意の文字列で置き換えることが可能である。FIG. 4 is an example of the surface of a combination lock. The dotted circle can be replaced with an arbitrary character string indicating a compounding ingredient, a sales company, or the like. 図５は、配合錠の裏面の例である。点線の円は、２以上の薬効成分の各々の一般名や含量等を示す任意の文字列で置き換えることが可能である。FIG. 5 is an example of the back surface of the combination lock. The dotted circle can be replaced with an arbitrary character string indicating the common name, content, etc. of each of the two or more medicinal ingredients.

以下で本発明の錠剤の表面と裏面の各々に記載された異なる情報が表示された医薬品包装箱又は其れを用いた医薬品情報の提供方法を詳細に説明する。但し以下の記載は本発明を説明するための例示であり、本発明の技術的範囲をこの記載範囲にのみ限定する趣旨ではない。 Hereinafter, a drug packaging box displaying different information described on the front surface and the back surface of the tablet of the present invention or a method for providing drug information using the same will be described in detail. However, the following description is an example for explaining the present invention, and does not mean that the technical scope of the present invention is limited only to this description range.

＜本発明に係る医薬品包装箱＞
本発明に係る医薬品包装箱は材質が紙であるものが好ましく、其の一部分に錠剤の表面と裏面の両面の画像が記載されたものである。錠剤の両面の印刷方法は、直接的に包装箱材に印刷を行う方法又は印刷を行った物品（シール等）を医薬品包装箱材に貼付する方法のいずれによっても可能である。尚、錠剤の両面の画像は、錠剤実物を撮影した写真や描画した絵図等から選ばれる。
錠剤の両面が記載された包装箱の一部分としては、未開封時に外部から目視が可能な包装箱の表面部分（図１においては、３、６、８、９、１０、１２のいずれかの部分）が好ましく、さらに好ましくは胴体部分（図１においては、３、６、９、１２のいずれかの部分）である。裏面部分は表面部分の反対側の面である。胴体部分（図１、２においては、１、３、６、９、１２の部分）とは、包装箱を成形させた際にフラップとなる部分（図１、２においては、２、４、５、７、８、１０、１１、１３の部分）を除く部分であり、胴体部分の縦の辺の両側にフラップが位置するように配置される。医薬品製品の包装箱は成形されたもの（図２）が医療現場に提供される。
包装箱は、医療現場で収納しやすいサイズであることが望ましい。成形されて且つ閉じられた包装箱のサイズは、好ましくは縦１０ｃｍ〜２０ｃｍで横３ｃｍ〜８ｃｍであり、より好ましくは縦１１ｃｍ〜１７ｃｍで横４ｃｍ〜７ｃｍである。 <Pharmaceutical packaging box according to the present invention>
The pharmaceutical packaging box according to the present invention is preferably made of paper, and an image of both the front surface and the back surface of the tablet is described in a part thereof. The printing method on both sides of the tablet can be either a method of directly printing on the packaging box material or a method of attaching the printed article (seal or the like) to the pharmaceutical packaging box material. The images on both sides of the tablet are selected from photographs taken of the actual tablets, drawn drawings, and the like.
As a part of the packaging box on which both sides of the tablet are described, the surface portion of the packaging box that can be visually recognized from the outside when unopened (any of 3, 6, 8, 9, 10, and 12 in FIG. 1). ) Is preferable, and a body portion (any of 3, 6, 9, and 12 in FIG. 1) is more preferable. The back surface portion is the surface opposite to the front surface portion. The body portion (parts 1, 3, 6, 9, and 12 in FIGS. 1 and 2) is a portion that becomes a flap when the packaging box is molded (in FIGS. 1 and 2, 2, 4, 5). , 7, 8, 10, 11 and 13), and the flaps are arranged so as to be located on both sides of the vertical side of the body portion. A molded packaging box for pharmaceutical products (Fig. 2) is provided to the medical field.
It is desirable that the packaging box has a size that is easy to store in the medical field. The size of the molded and closed packaging box is preferably 10 cm to 20 cm in length and 3 cm to 8 cm in width, and more preferably 11 cm to 17 cm in length and 4 cm to 7 cm in width.

＜本発明に係る錠剤の両面情報＞
本発明に係る錠剤の形態として、円形錠や異形錠等が挙げられるが、好ましくは円形錠である。本発明に係る錠剤に印字された文字は、表面と裏面にあることが好ましく、表面
と裏面に異なる文字情報が印字されていることが好ましい。錠剤には表面と裏面、側面等の面があるが、表面と裏面は互いに反対側に向かって開かれた面を有している。本明細書において“表面”とは“表面として扱った錠剤の片面”を、“裏面”とは“表面として扱った錠剤の片面の反対側の片面”を意味するに過ぎない便宜的に取り決めた用語であり、錠剤の一方の片面に表面又は裏面としての性質が当然に備えられている訳ではない。よって、同一錠剤の同一片面を表面として扱うか裏面として扱うかは個々の場合に応じて任意に行うことが可能である。
本発明に係る錠剤は、印字されるべき医薬情報量が多くなる傾向がある、２以上の薬効成分を含む配合錠であることが好ましい。本発明に係る配合錠の表面には、販売名の文字列から剤形、含量、会社名を示す文字列を除いた、錠剤中に配合された薬効成分を実質的に示す文字列又は其の略称（好ましくは薬効成分を実質的に示す文字列の略称の方）が印字される。本発明に係る略称は、医療従事者等の間で慣用的に使用されている名称であるものが好ましい。また配合錠の表面には、配合錠の文字列が印字してある方が錠剤情報を確認する需要者にとって好ましい。
本発明に係る配合錠の裏面には、配合錠に含まれる２以上の薬効成分の各々の一般名又はその略称が印字され、さらには２以上の薬効成分の各々のｍｇ又はμｇ単位での含量を示す数字が印字されていることが好ましい。 <Double-sided information on tablets according to the present invention>
Examples of the tablet form according to the present invention include a circular tablet, a deformed tablet, and the like, and a circular tablet is preferable. The characters printed on the tablet according to the present invention are preferably on the front surface and the back surface, and it is preferable that different character information is printed on the front surface and the back surface. Tablets have front and back surfaces, side surfaces and the like, but the front and back surfaces have surfaces that are open toward opposite sides. As used herein, the term "front side" means "one side of the tablet treated as the front side", and "back side" means "one side opposite to one side of the tablet treated as the front side". It is a term, and one side of a tablet does not naturally have the properties of a front surface or a back surface. Therefore, whether to treat the same one side of the same tablet as the front surface or the back surface can be arbitrarily performed according to each case.
The tablet according to the present invention is preferably a combination tablet containing two or more medicinal ingredients, which tends to increase the amount of pharmaceutical information to be printed. On the surface of the combination tablet according to the present invention, a character string indicating the medicinal ingredient contained in the tablet or a character string thereof, excluding the character string indicating the dosage form, the content and the company name from the character string of the brand name, or its The abbreviation (preferably the abbreviation of the character string substantially indicating the medicinal ingredient) is printed. The abbreviation according to the present invention is preferably a name commonly used among medical professionals and the like. Further, it is preferable that the character string of the combination tablet is printed on the surface of the combination tablet for the consumer who confirms the tablet information.
On the back surface of the combination tablet according to the present invention, the common name or an abbreviation of each of the two or more medicinal ingredients contained in the combination tablet is printed, and further, the content of each of the two or more medicinal ingredients in mg or μg. It is preferable that a number indicating is printed.

＜本発明に係る配合錠の具体例＞
本発明に係る配合錠として具体的には、バルサルタン及びアムロジピンベシル酸塩、アジルサルタン及びアムロジピンベシル酸塩、カンデサルタン及びアムロジピンベシル酸塩、カンデサルタン及びヒドロクロロチアジド、イルベサルタン及びアムロジピンベシル酸塩、オルメサルタンメドキソミル及びアゼルニジピン、バルサルタン及びヒドロクロロチアジド、クロピドグレル硫酸塩及びアスピリン、テルミサルタン及びアムロジピン、テルミサルタン及びヒドロクロロチアジド、トラマドール及びアセトアミノフェン、アムロジピンベシル酸塩及びアトルバスタチンカルシウム水和物、ロサルタンカリウム及びヒドロクロロチアジド、の何れかを含む配合錠が挙げられるが、特に好ましくはバルサルタン及びアムロジピンベシル酸塩を含む配合錠である。
配合錠は、含有される２以上の薬効成分の各々の一般名の組み合わせを用いる長い名称を含む販売名より、短い略称を含む販売名の方が正式な販売名として公的に採用されるのが一般的である。前文の長い名称・短い略称の組み合わせ例として、“アムロジピンベシル酸塩／バルサルタン”・“アムバロ”、“カンデサルタンシレキセチル／アムロジピンベシル酸塩”・“カムシア”、“テルミサルタン／アムロジピン”・“テラムロ”、“テルミサルタン／ヒドロクロロチアジド”・“テルチア”、“バルサルタン／ヒドロクロロチアジド”・“バルヒディオ”、“アムロジピンベシル酸塩／アトルバスタチンカルシウム水和物”・“アマルエット”、“ロサルタンカリウム/ヒドロクロロチアジド”・“ロサルヒド”、“カンデサルタン／ヒドロクロロチアジド”・“カデチア”、“イルベサルタン／アムロジピンベシル酸塩”・“イルアミクス”等が挙げられる。
販売名に採用された略称が配合錠に印字される場合、略称から各薬物の一般名を確信して予想することは困難であるため、それらの一般名も錠剤に印刷する必要が生じる。本発明に係る一般名は、国際一般名の日本語訳であることが好ましい。 <Specific Example of Combination Tablets According to the Present Invention>
Specifically, the combination tablets according to the present invention include balsartane and amlodipine besilate, azil sartane and amlodipine besilate, candesartan and amlodipine besilate, candesartan and hydrochlorothiazide, ilbesartan and amlodipine besilate, olmesartane medoxomil and azernidipine. Combination tablets containing any of balsartane and hydrochlorothiazide, clopidogrel sulfate and aspirin, thermisartan and amlodipine, thermisartane and hydrochlorothiazide, tramadol and acetaminophen, amlodipine besilate and atrubastatin calcium hydrate, rosartane potassium and hydrochlorothiazide can be mentioned. However, a combination tablet containing balsartane and amlodipine besilate is particularly preferable.
For combination tablets, a brand name containing a short abbreviation is officially adopted as a formal brand name rather than a brand name containing a long name that uses a combination of the common names of each of the two or more medicinal ingredients contained therein. Is common. Examples of combinations of long names and short abbreviations in the preamble are "Amlodipine besilate / amlodipine" / "Amlodipine", "Candesartan cilexetil / amlodipine besilate" / "Camcia", "Telmisartan / amlodipine" / "Terramuro". , "Telmisartan / Hydrochlorothiazide" / "Telcia", "Balsartan / Hydrochlorothiazide" / "Balhidio", "Amlodipine Besilate / Atrubastatin Calcium Hydrate" / "Amalette", "Rosartan Potassium / Hydrochlorothiazide" / "Losarhide", " Examples thereof include candesartan / hydrochlorothiazide, “cadetia”, “ilbesartan / amlodipine besylate”, and “ylamix”.
When the abbreviation adopted for the brand name is printed on the combination tablet, it is difficult to reliably predict the common name of each drug from the abbreviation, so it is necessary to print those common names on the tablet as well. The common name according to the present invention is preferably a Japanese translation of the international nonproprietary name.

＜本発明に係る錠剤の包装形態＞
本発明に係る錠剤の包装形態として、好ましくはアルミブリスター包装やＰＴＰ包装された形態である。更に必要に応じて、アルミピローで包装することが好ましい。 <Packaging form of tablets according to the present invention>
The packaging form of the tablet according to the present invention is preferably an aluminum blister package or a PTP package. Further, if necessary, it is preferable to wrap it in an aluminum pillow.

本発明によれば、包装箱及び錠剤を包む包装を開くことなく錠剤の両面に印字された情報を視認によって確認することが簡便に可能となった上で、錠剤の両面に異なる情報が印字された配合錠の積極的な開発及び医療現場への提供が今後更に期待される。また、錠剤
が手元に無くなった後も、包装箱自体を錠剤の両面に印字された情報を伝達するための道具として使用することが可能である。 According to the present invention, it is possible to easily visually confirm the information printed on both sides of the tablet without opening the packaging box and the packaging for wrapping the tablet, and different information is printed on both sides of the tablet. It is expected that the combination tablets will be actively developed and provided to the medical field in the future. Further, even after the tablet is lost, the packaging box itself can be used as a tool for transmitting information printed on both sides of the tablet.

１：側板（表面）、２：天蓋フラップ（表面）、３：側板（表面）、４：天蓋フラップ（表面）、５：内フラップ（表面）、６：側板（表面）、７：内フラップ（表面）、８：天蓋フラップ（表面）、９：側板（表面）、１０：天蓋フラップ（表面）、１１：内フラップ（表面）、１２：側板（表面）、１３：内フラップ（表面） 1: Side plate (surface) 2: Canopy flap (surface) 3: Side plate (surface) 4: Canopy flap (surface) 5: Inner flap (surface), 6: Side plate (surface), 7: Inner flap ( Surface), 8: Canopy flap (surface), 9: Side plate (surface), 10: Canopy flap (surface), 11: Inner flap (surface), 12: Side plate (surface), 13: Inner flap (surface)

Claims (5)

箱内部に収容された配合錠の表面と裏面の画像が、未開封時に外部から目視が可能な包装箱の表面部分に記載され、該画像が配合錠の表面と裏面で異なる薬剤情報が表示されている配合剤の画像であり、箱内部に収容された配合錠の表面には、配合成分を示す文字列又はその略称が印字され、配合錠の裏面には、配合錠に含まれる２以上の薬効成分の各々の一般名又は略称が印字された、医薬品包装箱。 Images of the front and back surfaces of the combination lock housed inside the box are described on the front surface of the packaging box that can be visually viewed from the outside when unopened, and the images are displayed with different drug information on the front and back surfaces of the combination lock. It is an image of the compounding agent, and the character string indicating the compounding component or its abbreviation is printed on the surface of the compounding tablet housed inside the box, and two or more contained in the compounding tablet are printed on the back surface of the compounding tablet. A pharmaceutical packaging box on which the generic name or abbreviation of each medicinal ingredient is printed. 箱内部に収容された配合錠の表面には、さらに、薬効成分の一般名又はその略称、含有量、又は/及び製造販売会社名が印字された、請求項１に記載の医薬品包装箱。 The pharmaceutical packaging box according to claim 1, wherein the generic name of the medicinal ingredient or its abbreviation, content, or / and the name of the manufacturing and sales company are further printed on the surface of the combination lock contained in the box. 箱内部に収容された配合錠の表面には、配合錠の文字列が印字され、配合錠の裏面には、２以上の薬効成分の各々の含量をｍｇ又はμｇの単位で示す数字が印字された、請求項１または２に記載の医薬品包装箱。 The character string of the combination tablet is printed on the front surface of the combination tablet housed inside the box, and the number indicating the content of each of the two or more medicinal ingredients in mg or μg is printed on the back surface of the combination tablet. The pharmaceutical packaging box according to claim 1 or 2. 配合錠の表面と裏面の画像が写真又は絵図である、請求項１〜３のいずれかに記載の医薬品包装箱。 Front and back side image of Combination Tablets are photographs or pictorial, pharmaceutical packaging box according to any one of請Motomeko 1-3. 配合錠が、バルサルタン及びアムロジピンベシル酸塩、アジルサルタン及びアムロジピンベシル酸塩、カンデサルタン及びアムロジピンベシル酸塩、カンデサルタン及びヒドロクロロチアジド、イルベサルタン及びアムロジピンベシル酸塩、オルメサルタンメドキソミル及びアゼルニジピン、バルサルタン及びヒドロクロロチアジド、クロピドグレル硫酸塩及びアスピリン、テルミサルタン及びアムロジピン、テルミサルタン及びヒドロクロロチアジド、トラマドール及びアセトアミノフェン、ロサルタンカリウム及びヒドロクロロチアジド、のいずれかの２つの薬効成分を含む、請求項１〜４のいずれかに記載の医薬品包装箱。 Combination tablets include balsartan and amlodipine besilate, azilsartan and amlodipine besylate, candesartan and amlodipine besylate, candesartan and hydrochlorothiazide, ilbesartan and amlodipine besylate, azilsartan medoxomil and azernidipine, balsartan and hydrochlorothiazide, clopidogrel sulfate. The pharmaceutical packaging box according to any one of claims 1 to 4, which comprises any two medicinal ingredients of aspirin, azilsartan and amlodipine, thermisartan and hydrochlorothiazide, tramadol and acetaminophen, rosartan potassium and hydrochlorothiazide.
JP2021133370A 2015-11-30 2021-08-18 Method for Providing Double-Sided Printed Information on Combination Tablets Using Pharmaceutical Packaging Boxes Active JP7334218B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015234112 2015-11-30
JP2015234112 2015-11-30
JP2015235147A JP6967833B2 (en) 2015-11-30 2015-12-01 How to provide double-sided printing information for compound locks using a pharmaceutical packaging box

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015235147A Division JP6967833B2 (en) 2015-11-30 2015-12-01 How to provide double-sided printing information for compound locks using a pharmaceutical packaging box

Publications (2)

Publication Number Publication Date
JP2021192797A true JP2021192797A (en) 2021-12-23
JP7334218B2 JP7334218B2 (en) 2023-08-28

Family

ID=59058043

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015235147A Active JP6967833B2 (en) 2015-11-30 2015-12-01 How to provide double-sided printing information for compound locks using a pharmaceutical packaging box
JP2021133370A Active JP7334218B2 (en) 2015-11-30 2021-08-18 Method for Providing Double-Sided Printed Information on Combination Tablets Using Pharmaceutical Packaging Boxes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015235147A Active JP6967833B2 (en) 2015-11-30 2015-12-01 How to provide double-sided printing information for compound locks using a pharmaceutical packaging box

Country Status (1)

Country Link
JP (2) JP6967833B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6914604B2 (en) * 2018-09-10 2021-08-04 Ckd株式会社 PTP sheet and PTP packaging machine
JP7219241B2 (en) * 2020-03-05 2023-02-07 Ckd株式会社 Blister sheet, manufacturing method thereof, and blister packaging machine

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3030269U (en) * 1996-03-22 1996-10-22 株式会社旭 Medicine bag
JP3075682U (en) * 2000-08-16 2001-02-27 医療法人伊丹中央町クリニック Drug explanation sticker and medicine bag with it attached
JP2003316903A (en) * 2002-04-15 2003-11-07 Hewlett Packard Co <Hp> Prescription pharmaceutical labelling system
JP2004189703A (en) * 2002-12-13 2004-07-08 Mitsubishi Pharma Corp Scored tablet
JP2005343515A (en) * 2004-06-03 2005-12-15 Ckd Corp Blister packaging machine and tablet
JP2006504583A (en) * 2002-03-13 2006-02-09 フクスベルガー，パブロ Pharmaceutical packaging having capsule, tablet or similar form
JP2007319479A (en) * 2006-06-01 2007-12-13 Meding:Kk Medicine pouch
JP3172099U (en) * 2011-09-22 2011-12-01 康男 広瀬 Packaging container
JP2013040165A (en) * 2011-07-15 2013-02-28 Sawai Pharmaceutical Co Ltd Method for marking uncoated tablet
JP2013049453A (en) * 2011-08-31 2013-03-14 Ckd Corp Ptp sheet and apparatus for manufacturing the same
WO2013140821A1 (en) * 2012-03-23 2013-09-26 第一三共株式会社 Layered body for ptp or blister pack, and ptp or blister pack
JP2014064730A (en) * 2012-09-26 2014-04-17 Terumo Corp Pharmaceutical patch package
WO2014058047A1 (en) * 2012-10-12 2014-04-17 味の素株式会社 Method for producing pharmaceutical preparation containing calcium antagonist/angiotensin ii receptor antagonist
JP3196225U (en) * 2014-12-16 2015-02-26 大原薬品工業株式会社 Packaging box for pharmaceutical products with pharmaceutical information on the back of the flap

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3030269U (en) * 1996-03-22 1996-10-22 株式会社旭 Medicine bag
JP3075682U (en) * 2000-08-16 2001-02-27 医療法人伊丹中央町クリニック Drug explanation sticker and medicine bag with it attached
JP2006504583A (en) * 2002-03-13 2006-02-09 フクスベルガー，パブロ Pharmaceutical packaging having capsule, tablet or similar form
JP2003316903A (en) * 2002-04-15 2003-11-07 Hewlett Packard Co <Hp> Prescription pharmaceutical labelling system
JP2004189703A (en) * 2002-12-13 2004-07-08 Mitsubishi Pharma Corp Scored tablet
JP2005343515A (en) * 2004-06-03 2005-12-15 Ckd Corp Blister packaging machine and tablet
JP2007319479A (en) * 2006-06-01 2007-12-13 Meding:Kk Medicine pouch
JP2013040165A (en) * 2011-07-15 2013-02-28 Sawai Pharmaceutical Co Ltd Method for marking uncoated tablet
JP2013049453A (en) * 2011-08-31 2013-03-14 Ckd Corp Ptp sheet and apparatus for manufacturing the same
JP3172099U (en) * 2011-09-22 2011-12-01 康男 広瀬 Packaging container
WO2013140821A1 (en) * 2012-03-23 2013-09-26 第一三共株式会社 Layered body for ptp or blister pack, and ptp or blister pack
JP2014064730A (en) * 2012-09-26 2014-04-17 Terumo Corp Pharmaceutical patch package
WO2014058047A1 (en) * 2012-10-12 2014-04-17 味の素株式会社 Method for producing pharmaceutical preparation containing calcium antagonist/angiotensin ii receptor antagonist
JP3196225U (en) * 2014-12-16 2015-02-26 大原薬品工業株式会社 Packaging box for pharmaceutical products with pharmaceutical information on the back of the flap

Also Published As

Publication number Publication date
JP2017104146A (en) 2017-06-15
JP6967833B2 (en) 2021-11-17
JP7334218B2 (en) 2023-08-28

Similar Documents

Publication Publication Date Title
JP2021192797A (en) Providing method of double-sided printing information of combination tablet utilizing pharmaceutical packaging box
US3504788A (en) Package
ES2364510T4 (en) Packaging for films containing active substance and manufacturing procedures
CN102145780B (en) Peelable packaging containing dosage form and for the method forming peelable packaging
US4189053A (en) Bulk unit of use informational medicinal dispensing system
Church et al. How stable are medicines moved from original packs into compliance aids?
Lockhart et al. Packaging of pharmaceuticals and healthcare products
US20140081203A1 (en) Container for administering medication
US9278050B2 (en) Dissolvable medication administration bag and method of using the same
Swaroop et al. A glimpse on expiry date of pharmaceutical dosage forms
US20090127155A1 (en) Packaging for unitary dosage items
Thunga et al. Solid Dosage Forms: A Detailed Research on Non-conforming Product Quality.
JP5588881B2 (en) Dose setting package
JPH01502511A (en) Device for administering pharmaceuticals
FR2901047A1 (en) LABEL TO BE ATTACHED TO PHARMACEUTICAL, PARAPHARMACEUTICAL, PHITOSANITARY AND SIMILAR PRODUCTS
JP2009208831A (en) Erroneous intake preventing box
JP3196225U (en) Packaging box for pharmaceutical products with pharmaceutical information on the back of the flap
JP2008094426A (en) Packaging bag
JP6698295B2 (en) Multipurpose sheet for pharmaceutical packaging and case base material for pharmaceutical packaging
JP3127941U (en) Onepus2tablets packaging container
JP3231643U (en) Multipurpose sleeve for PТP seat
JP3214867U (en) Drug package
JP2003226360A (en) Press-through-pack package with operating instruction mount
JP7340595B2 (en) A ready-for-sale packaging unit containing at least one pharmaceutical product, a set comprising a plurality of such packaging units, and a method for producing such packaging units
JP2016146940A (en) Dosing object package

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221118

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230622

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230816

R150 Certificate of patent or registration of utility model

Ref document number: 7334218

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150